Betalain-Rich Red Beet Extract and Osteoarthritis Discomfort

Why the Study Tested Betalain-Rich Red Beet Extract in Osteoarthritis

The paper begins from the observation that people with osteoarthritis commonly experience progressive discomfort related to pain, joint stiffness and general tiredness. The authors also note that non-steroidal anti-inflammatory drugs are commonly used but describe their efficacy as not completely satisfactory. Against that background, the study investigated a betalain-rich red beet extract as a possible approach to reducing OA-associated discomfort. The aim stated in the study was to test doses from 35 to 100 mg twice daily.

The Intervention Focused on a Short Ten-Day Treatment Period

Participants with osteoarthritis symptoms received the red beet extract twice daily for 10 days. The short intervention period allowed researchers to assess changes in reported discomfort and selected blood biomarkers. This was therefore a short intervention designed to track changes over days rather than months. The participant count and demographic characteristics are not specified in the study summary, limiting assessment of the sample’s representativeness.

How Pain, Energy and Blood Markers Were Evaluated

The investigators evaluated McGill and Energy Score data on days 1, 5 and 10. These repeated assessments allowed them to examine whether reported discomfort changed during the treatment period. The study also measured serum advanced oxidation protein products, abbreviated AOPP, with a commercial kit. In addition, sera from volunteers treated with the extract were subjected to a cytokine and chemokine array.

The Study Combined Symptom Scores With Biochemical Measurements

This combination is important because the research did not rely only on a pain-related score. It also examined circulating markers that the authors connected with oxidative and inflammatory processes. The study reported findings for AOPP and TNF-alpha, but complete numerical results for the full cytokine and chemokine array were not presented in the summary.

Table 1. Measures and Timing Reported in the Osteoarthritis Study

Table note: Complete numerical Energy Score and cytokine-array results were not reported.

What Happened to McGill Scores During Red Beet Extract Treatment

The collected data showed that ingestion of red beet extract for 10 days reduced McGill scores in a time- and dose-dependent manner. The maximum reported reduction was 33% compared with the first day of treatment. The authors concluded that doses greater than 35 mg had a beneficial effect on pain associated with osteoarthritis conditions. The intervention involved multiple doses, so the observed response cannot be attributed to one universally effective dose. During the 10-day study, changes in pain-related scores varied across the treatment periods and doses examined by the researchers. However, these short-term findings do not establish whether the improvements would persist beyond the treatment period or occur consistently in a larger patient population.

The Maximum Reported Reduction Reached Thirty-Three Percent

The maximum reported reduction in McGill scores was 33% relative to the first day of treatment. This figure represents the largest observed improvement rather than an average reduction across all participants. The absence of complete group-level scores for each dose limits the assessment of response consistency across the study population. It remains unclear whether improvements were broadly distributed among participants or influenced by individual responses. More detailed results would help clarify how pain scores changed at different doses and whether higher doses consistently produced greater reductions. The 33% finding therefore provides an indication of the potential magnitude of the short-term response without establishing a predictable treatment effect for every participant.

Table 2. Main Symptom and Biomarker Changes Reported

Table note: These figures describe maximum reductions or a defined subgroup; complete group-level numerical results were not reported.

How TNF-Alpha Changed in a Subgroup of Study Participants

The investigators also reported a subgroup finding for tumour necrosis factor alpha, or TNF-alpha, an inflammatory signaling protein. Serum TNF-alpha levels were reduced in subjects whose concentrations exceeded 1 pg/mL before treatment began. This qualification is important because the observed reduction was not reported as a uniform response across all participants. Instead, it specifically concerned individuals whose baseline TNF-alpha levels were above the stated threshold. The finding suggests a measurable biochemical response within this subgroup, but it does not establish whether participants with lower initial concentrations experienced similar changes. Without detailed results for each subgroup, the relationship between TNF-alpha reduction, treatment response and improvements in osteoarthritis-related discomfort remains uncertain.

The TNF-Alpha Result Should Not Be Generalized to the Entire Sample

The reduction was reported only among participants whose baseline TNF-alpha exceeded 1 pg/mL. Without detailed subgroup results, the finding cannot be extended to all participants or interpreted as evidence of a general clinical anti-inflammatory effect. The cytokine result is best presented as an observed serum change in participants with baseline TNF-alpha above 1 pg/mL, rather than as proof of a broad anti-inflammatory clinical effect. This distinction is important because changes in circulating inflammatory markers do not necessarily correspond to improvements in symptoms or functional outcomes. The relationship between TNF-alpha reduction and the reported changes in pain scores therefore remains uncertain.

What the AOPP Result Suggests About Protein Oxidation

The study measured advanced oxidation protein products (AOPP), markers associated with oxidative modification of proteins, including reactions involving hypochlorous acid or hypochlorites. After 10 days of treatment, serum AOPP levels were reduced by as much as 48%. The authors used this result to propose a possible mechanism for the betalain-rich red beet extract. They suggested that the extract might inhibit protein oxidation associated with hypochlorous acid released by activated neutrophils. This interpretation connects the observed biochemical response with processes involved in oxidative stress. However, the reduction in AOPP alone cannot establish which molecular pathways were affected or whether the proposed mechanism directly influenced the participants' symptoms.

AOPP Fell by Up to Forty-Eight Percent After Ten Days

The reduction in AOPP suggests that changes in protein oxidation accompanied the intervention. However, the reported biomarker response does not establish that reduced protein oxidation was responsible for the improvement in discomfort scores. The result therefore indicates a biochemical change observed during the intervention, while the proposed mechanism remains an interpretation offered by the study authors. The magnitude of the reported reduction is notable, but its clinical significance cannot be determined from the percentage change alone. Further evidence would be needed to establish whether similar biochemical responses occur consistently and whether they correspond to meaningful improvements in osteoarthritis-related symptoms.

How the Clinical and Biochemical Findings Fit Together

The paper presents the McGill, TNF-alpha and AOPP findings as related parts of the response to betalain-rich red beet extract. Pain-related scores declined while selected serum measurements also changed during the 10-day intervention. This pattern led the authors to describe the extract as beneficial for pain associated with osteoarthritis conditions at doses greater than 35 mg. The researchers also proposed that inhibition of protein oxidation might help explain the biochemical findings.

The Findings Combine Reported Discomfort With Laboratory Biomarkers

Symptom scores and serum biomarkers represent different types of endpoints and should not be treated as interchangeable measures of treatment effectiveness. Changes in McGill scores reflect participants' reported discomfort, whereas TNF-alpha and AOPP measurements provide information about inflammatory signaling and protein oxidation. A reduction in either biomarker does not independently establish the magnitude of clinical pain relief or confirm that biochemical changes caused the observed improvement. The study identified parallel changes in discomfort scores and selected serum markers during a 10-day intervention with betalain-rich red beet extract. However, the relationship between these outcomes remains uncertain, and their simultaneous improvement does not demonstrate a direct causal connection.

What the Short Study Cannot Establish About Treatment

The total sample size, the inclusion of a control group, and the use of randomization or blinding remain unclear. These methodological uncertainties limit the reliability of the reported outcomes and make it difficult to attribute improvements specifically to the red beet extract. Changes in discomfort scores may also reflect natural symptom fluctuations or other factors unrelated to treatment. The intervention lasted only 10 days, providing evidence of short-term responses rather than sustained effects. Consequently, the findings cannot establish whether reductions in discomfort or biochemical markers would persist with longer use.

The Study Does Not Support Replacing Standard Osteoarthritis Care

The authors discussed limitations of NSAID treatment as background, but no direct comparison between red beet extract and conventional NSAIDs was reported. The findings therefore do not establish that the extract provides equivalent pain relief or can replace standard osteoarthritis treatment. Instead, the researchers observed changes in discomfort scores and selected biochemical markers during a short intervention. They also proposed that reduced protein oxidation might contribute to these effects, although the mechanism remains unconfirmed. Further controlled studies are needed to evaluate clinical effectiveness, safety and longer-term outcomes.

Table 3. Findings and Unresolved Questions From the Study

Table note: The observed short-term outcomes do not establish longer-term effectiveness or comparative clinical benefit.

Why the Study Is Best Read as Preliminary Clinical Evidence

The study is informative because it combines repeated symptom assessments with serum measurements over a defined 10-day intervention. It also reports time- and dose-related changes in McGill scores, alongside changes in selected biochemical markers. However, important methodological details, including sample size, control-group information and randomization procedures, remain unclear. These limitations make it difficult to determine whether the observed improvements were directly attributable to the intervention. The short treatment period also restricts conclusions about long-term effectiveness and the consistency of responses across different patient groups.

The Results Support Further Study Rather Than a Definitive Treatment Claim

The reported 33% maximum McGill-score reduction and 48% maximum AOPP reduction provide specific signals for further investigation. The TNF-alpha finding adds another possible biological marker in a defined subgroup. Together, these observations warrant further investigation but do not establish betalain-rich red beet extract as a proven treatment for osteoarthritis.

Practical takeaway: Pietrzkowski and colleagues reported that 10 days of betalain-rich red beet extract was associated with time- and dose-dependent reductions in McGill scores, with a maximum 33% reduction from day 1. AOPP fell by up to 48%, and TNF-alpha decreased in participants whose baseline level exceeded 1 pg/mL. These short-term observations and the proposed protein-oxidation mechanism require further controlled investigation before the extract can be considered an established osteoarthritis treatment.

Frequently asked questions

Natalie Brooks — author

Natalie Brooks writes with an editorial focus on interdisciplinary research, scientific reviews, evidence synthesis and studies that combine findings produced through different research methods. At CAB Direct, Natalie covers research reviews, emerging evidence...